Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A. Ference, Alberico L. Catapano, Børge G. Nordestgaard et al.|European Heart Journal|2017Cited by 3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyBørge G. Nordestgaard, M. John Chapman, Steve E. Humphries et al.|European Heart Journal|2013Cited by 2.7k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus PanelJan Borén, Henry N. Ginsberg, M. John Chapman et al.|European Heart Journal|2020Cited by 1.5k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsMarc S. Sabatine, Evan A. Stein, Robert P. Giugliano et al.|New England Journal of Medicine|2015Cited by 1.5k
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Stanley T. Crooke, Raúl D. Santos et al.|The Lancet|2010Cited by 905